- Platform combines the innate immuno-stimulatory effect of the myxoma virus with anti-tumor immune stimulation that uniquely target multiple aspects of cancer immunity to treat solid tumors and hematological cancers
- OncoMyx is developing a next generation oncolytic virus platform including the capacity for multi-arming with a nonpathogenic virus which allows for intravenous (IV) and repeat dosing
- Proceeds of the financing will support the advancement of the company’s lead program into clinical trials with IV dosing and development of the pipeline to target critical anti-tumor immune mechanisms
Author Archive: AZBio
Investments drive the growth of Arizona’s innovation sector
As Arizona continues to recover from the economic challenges caused by the pandemic, investment in our innovation sector is an essential component of our state’s current and future growth strategies. Announcements of major new investments in Arizona by global leaders including BD, Exact Sciences, Intel, and TSMC are big news today. Yet, our greatest potential for future growth comes from the young companies that are emerging in our tech and medtech sectors.Continue reading
Researchers Receive $15.7 Million NIH Grant for the Arizona Alzheimer’s Disease Research Center
Grant will continue to support Arizona’s leadership roles in the fight against Alzheimer’s disease and related dementiasContinue reading
GlobalMed Expands its Virtual Health Rental Program to Include More Offerings
The CostSimplified® virtual health rental program expands offerings with newly added telehealth delivery stations and medical devices.Continue reading
Meet the 2021 Arizona Innovation Challenge Awardees
ARIZONA COMMERCE AUTHORITY ANNOUNCES AWARDEES FOR THE 2021 ARIZONA INNOVATION CHALLENGE
Of the ten awardees, five are bio & life science companies: Navi Nurses, ReSuture, SaiOx Inc., TapRoot Interventions & Solutions, and The Patient Company
Continue reading
NeoLight Acquires Phoenix Technology Group
Scottsdale, AZ, Nov 17, 2021—NeoLight LLC (NeoLight), an ASU spinout and an Arizona based newborn medical device company, today announced it has acquired Phoenix Technology Group LLC (PTG), a leading provider of advanced ophthalmic imaging devices, including a telemedicine platform for retinopathy of prematurity (ROP) screening, a leading cause of blindness in premature infants. The acquisition will expand the NeoLight product portfolio to include the ocular imaging devices Phoenix ICON™, Phoenix ICON™ GO, and the telemedicine platform Phoenix CONNECT™ (previously known as FocusROP). These products provide advanced ocular imaging through lens and light innovation, providing stunning ocular images that give clinicians the needed speed, confidence, and connectivity for patient exams.Continue reading
TGen’s Annual Economic Impact on Arizona Exceeds Half a Billion Dollars
Latest economic-impact report shows that TGen returns $132 for every $1 invested by the State of ArizonaContinue reading
Health Futures: Joan Koerber-Walker and Bob Roth Discuss Health Innovation
AZBio president & CEO, Joan Koerber-Walker, joins Bob Roth on Health Futures to discuss health innovation, the importance of making good choices during the pandemic, and why AZBio is helping to build AZAdvances. Continue reading
UArizona Researcher Will Screen Drug Combos That Might Lengthen Our Lives
Funded by the National Academy of Medicine, Dr. George Sutphin will conduct a high-throughput screen of life-extending compounds in roundworms.Continue reading
UArizona Researchers Develop Ultra-Thin ‘Computer on the Bone’
osseosurface electronic device applied to a synthetic bone Osseosurface electronic devices, which attach directly to the bone, could one day help physicians monitor bone health. It’s show here applied to a synthetic bone in the Gutruf Lab at the University of Arizona. Image Courtesy of Gutruf Lab
Engineers and physicians teamed up to develop a wireless device to monitor and protect bone health.Continue reading